Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
04 2021
Historique:
received: 06 09 2020
revised: 15 11 2020
accepted: 23 11 2020
entrez: 22 5 2021
pubmed: 23 5 2021
medline: 22 9 2021
Statut: ppublish

Résumé

Some severe asthmatic patients experience frequent bacterial respiratory tract infections, which contribute significantly to their disease burden, and often are attributed to their use of systemic corticosteroids and comorbid bronchiectasis. We report a case of a 58-year-old woman who had prednisone-dependent asthma and exacerbations with intense mixed eosinophilic and neutrophilic bronchitis. Autosomal dominant hyper-IgE syndrome, which is a primary immunodeficiency characterized by elevated IgE, eosinophilia, and recurrent infections, caused by a novel pathogenic mutation in STAT3 was identified as the cause of her airway disease. We believe that this is the first report of the demonstration of an IL-5 driven eosinophilia that is associated with a STAT3 mutation that was treated successfully with an anti-IL5 biological.

Identifiants

pubmed: 34022014
pii: S0012-3692(20)35331-9
doi: 10.1016/j.chest.2020.11.042
pii:
doi:

Substances chimiques

Anti-Asthmatic Agents 0
Antibodies, Monoclonal, Humanized 0
Glucocorticoids 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
benralizumab 71492GE1FX
DNA 9007-49-2
Prednisone VB0R961HZT

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e181-e184

Informations de copyright

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Adil Adatia (A)

Firestone Institute for Respiratory Health, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; Division of Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada.

Christopher J Allen (CJ)

Firestone Institute for Respiratory Health, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; Division of Respirology, McMaster University, Hamilton, ON, Canada.

Joshua Wald (J)

Firestone Institute for Respiratory Health, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; Division of Respirology, McMaster University, Hamilton, ON, Canada.

Carl D Richards (CD)

Division of Molecular Medicine, McMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Susan Waserman (S)

Division of Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada.

Parameswaran Nair (P)

Firestone Institute for Respiratory Health, St Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; Division of Respirology, McMaster University, Hamilton, ON, Canada. Electronic address: parames@mcmaster.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH